Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ensitrelvir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Shionogi Secures FDA Approval For First Post-Exposure Covid
    Shionogi Secures FDA Approval For First Post-Exposure Covid

    01 Jun 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-regulator-approves-oral-drug-japans-shionogi-prevent-covid-19-2026-06-01/

    REUTERS
    01 Jun 2026
    Share Share
    NEJM: Shionogi's Ensitrelvir Prevents COVID-19 After Exposure
    NEJM: Shionogi's Ensitrelvir Prevents COVID-19 After Exposure

    13 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260513512740/en/New-England-Journal-of-Medicine-Publishes-Shionogi-Study-Demonstrating-Ensitrelvir-Prevents-COVID-19-Following-Exposure

    BUSINESSWIRE
    13 May 2026
    Share Share
    CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir Prevents COVID
    CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir Prevents COVID

    12 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250311777665/en

    BUSINESSWIRE
    12 Mar 2025
    Share Share
    Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial
    Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial

    13 May 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/japans-shionogi-says-covid-treatment-did-not-meet-endpoint-late-stage-trial-2024-05-13/

    REUTERS
    13 May 2024
    Share Share
    Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness
    Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness

    11 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231010759997/en

    BUSINESSWIRE
    11 Oct 2023
    Share Share
    Shionogi Presents New Ensitrelvir Clinical and Real-World Data
    Shionogi Presents New Ensitrelvir Clinical and Real-World Data

    18 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230918485005/en

    BUSINESSWIRE
    18 Sep 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.